How We Approach Suppressive Antibiotic Therapy (SAT) Following Debridement, Antibiotics, and Implant Retention for Prosthetic Joint Infection

The optimal treatment of prosthetic joint infection (PJI) remains uncertain. Patients undergoing debridement, antibiotics, and implant retention (DAIR) receive extended antimicrobial treatment, and some experts leave patients at perceived highest risk of relapse on suppressive antibiotic therapy (SAT). In this narrative review, we synthesize the literature concerning the role of SAT to prevent treatment failure following DAIR, attempting to answer 3 key questions: (1) What factors identify patients at highest risk for treatment failure after DAIR (ie, patients with the greatest potential to benefit from SAT), (2) Does SAT reduce the rate of treatment failure after DAIR, and (3) What are the rates of treatment failure and adverse events necessitating treatment discontinuation in patients receiving SAT? We conclude by proposing risk-benefit stratification criteria to guide use of SAT after DAIR for PJI, informed by the limited available literature. Limited data suggest suppressive antibiotic therapy (SAT) may reduce treatment failure following debridement and implant retention (DAIR) for prosthetic joint infection. We propose a structured approach to selecting patients for SAT following DAIR incorporating known DAIR treatment failure risk factors.

Automated summary

This narrative review synthesizes the literature on the role of suppressive antibiotic therapy (SAT) to prevent treatment failure after debridement, antibiotics, and implant retention (DAIR) for prosthetic joint infection. It aims to answer three key questions: (1) the identification of patients at highest risk for treatment failure after DAIR, (2) the effectiveness of SAT in reducing treatment failure rate after DAIR, and (3) the rates of treatment failure and adverse events in patients receiving SAT. The review proposes risk-benefit stratification criteria for selecting patients for SAT following DAIR.